Prof. Martin is Profesor at the University of Granada (Spain) and Principal Investigator of the Gene and Cell therapy group at GENYO. His activity in the last 30 years has been focused on developing new, more efficient and safer gene transfer systems for application in advanced therapies for the treatment of cancer and rare diseases, with 10 international patents and more than 70 publications in top journals, cited in more than 1500 times. Francisco was a postdoc at the Institute for Cancer Research (ICR), Windeyer Institute of Medical Sciences (UCL) in London (UK), focusing on vector development. Currently, is interest is focused on the optimization of gene therapy and gene editing tools for improved Advanced medicinal products (ATMPs) in unmet medical cancers and Pompe-disease.

Carlos Martín Molina has more than 19 years of experience in the Management and Direction of large projects of first-rate international companies. His main function is the Execution and Monitoring of Strategic Plans, Human Resources Management, Planning of Term Objectives, Cost and Sales and Team Management. He has founded several companies such as Bioceramic, Debla Desarrollo e Infraestructuras, CRISPNA, Facial Team, a company in the health sector, a pioneer worldwide for the type of treatments that performs. In 2017, he founded LentiStem Biotech, S.L. of which he is a founding partner and sole administrator.

Graduated with honors in Biotechnology and Master of Sciences in Advanced Immunology (University of Granada 2016). She  performed her PhD in Biomedicine under the supervision of Prof. Francisco Martin at GENYO (Granada), co-developing the state-of-the art of current LentiStem’s technologies for the optimization of gene expression control in engineered cells for immunotherapy and CAR-T cells. She has over 6 years of experience in T cells, HSCs and lentiviral vectors for gene therapy and biotech, becoming a co-founder member of LentiStem during the PhD. She is co-author of 16 publications and 2 patents.

raduated in Biotechnology at the University of Granada. In 2018, he completed the Master’s Degree Work on a gene therapy project for cancer immunotherapy. In 2019, he was hired by LentiStem Biotech after getting an Industrial PhD, where he begins with the realization of his doctoral thesis in parallel with the development of the activity of the working on the development of 4th generation inducible CARs, as well as in optimizing and improving the production of lentiviral vectors.

Graduated in Biology from the University of Salamanca and has a Master’s degree in Genetics from the International Graduate School of the University of Granada. During the last course of the degree she enjoyed a Collaboration Scholarship in Departments of the Ministry of Education, in the Laboratory of Functional Genetics of Rare Diseases of the Department of Microbiology and Genetics of the Faculty of Biology. She joined the Gene and Cell Therapy group to carry out her Master’s Thesis, about the use of lentiviral vectors of physiological expression to improve anti-HER2 CAR-T cell therapy. 

Inventor of the first agent-based drug approved in the United States using injectable micro technology (Varithena®). Passionate about science and community service. Determined to work hard to create valuable products and make them serve in the market. High experience in different biotech and biomedical international business.

Full professor at the Anatomy and Embriology University of Granada. Co-founder of EBT Regemat 3D and Spin-off PKRExogenetics S.L. and scientific advisor to Propanc Health Group Corporation. Academic Member of the Real Academy of Medicine and Surgery of Granada. He is a key expert in pancreatic cancer research, animal modeling, nanotechnology, 3D-bio impression and regenerative medicine.

Tax and accounting advisor with more than 20 years of experience in the entire cycle of general accounting. She has extensive experience in all tax returns that have been filed with the Tax Agency. Presentation of appeals against notifications and claims from the State Tax Agency and the Junta de Andalucía with more than 90% success. Extensive experience in accounting for SMEs and Large companies, presenting all the annual, quarterly or monthly models that these companies have to present to the state and regional tax agency. Co-founder and CAO of LentiStem Biotech.

Miguel has been focused in the development of therapeutic strategies based in the genetic modification of the cell’s genome to phenotypically restore a defect or to provide a novel function. He performed his PhD under Francisco Martin’s supervision in gene therapy vectors and joined to the Doina Ganea’s group (US) as postdoc. He is currenty the Head of Laboratory in Amarna Therapeutics, a company focused in the development of lentiviral vector for autoimmune diseases. He is co-author of several patents, and co-founder of Ariddad Therapeutics SL. 

Graduated in Biology in 1998 from the University of Alicante, and PhD in Biology in 2001 from the Autonomous University of Madrid. Her work has resulted in the publication of 41 scientific articles in high-impact journals, 9 of them as first author and 5 as corresponding author. She has been awarded an “EMBO Long Term Post-Doctoral Fellowship”, “HRB Post-doctoral Research Fellowship” and a L’Oréal-UNESCO For Women in Science Research Exchange to develop her work focused on the study of the Acute megakaryoblastic childhood leukemia. 

Full professor at the Department of Human Anatomy and Embryology, School of Medicine and member of the Institute of Biopathology and Regenerative Medicine, University of Granada, Spain. She got her Ph.D. in 2002 in this university working on suicide gene therapy applied to cancer and received the 2006 PhD Excellence award for her dissertation. She is a Corresponding Member of the Royal Academy of Medicine and Surgery of Granada District since 2002. She received 8 research awards, among them the Award of the Social Council of the University of Granada to the “Best Investigating Trajectory of Young Researchers” (2009) and “February 28 award for the professional career” of the city council in 2021. She is the inventor of 14 patents, one of these (P 201300753) has been licensed to the company VIDIA HEALTH S.A.

President of the Spanish Stock Market, Member of Board director SIX-European Stock Market.

Founder and CEO of Lamark Therapeutics. Cellular biologist, biochemist and entrepreneur dedicated to translational research in aging and cancer. Doctor (PhD) and Biochemistry and Molecular Biology from the Indian Institute of Sciences (2004-2009), and in Philosophy. MSc Biotechnology at Hemwati Nandan Bahuguna University of Garhwal (2002 – 2004), Introduction to Corporate Finance (2018) at The Corporate Finance Institut® (CFI). CSO of LentiStem Biotech from October 2018 to July 2019.

Doctor of Dentistry and entrepreneur of an avant-garde clinic. Professor of Oral Surgery and Implantology. University of Granada. Adjunct Clinical Associate Professor, Periodontics and Oral Medicine Department (University of Michigan, USA). Visiting Professor, Periodontics Department (University of Iowa, USA). He was awarded a European Fellowship in Oral Surgery by the EFOSS Diplomate and Fellowship of the International Congress of Oral Implantologists. He is the author of more than 180 international JCR publications and various patents. He is a researcher of various national and international projects. International speaker on Oral Surgery and Implantology.

Doctor of Pharmacy from the University of Granada. Post-doctoral stay at the Combinatorial Center of Excellence in Southampton (England 2002-2005 and in the Mark Bradley Group at the University of Edinburgh (Scotland). In 2008, he obtained his first IP project that allowed him to develop the use of dynamic chemistry for DNA reading, being the inventor of the patent that protects this technology. In 2010 he founded DestiNA Genomics Ltd and also is the CSO and Director. Coordinator of several multidisciplinary projects focused on the development of chemical platforms. In 2012, she was awarded a Marie Curie CIG reintegration fellowship. On the other hand, Dr. Mochón has helped incorporate DestiNA Genomics S.L. in Spain as a subsidiary of the Scottish company. In July, DestiNA successfully closed a capital increase worth €1.2m that has allowed the incorporation of an important Andalusian business group that operates in the Clinical Analysis, Pathological Anatomy, and Biomedical Research sectors.